Welcome to our dedicated page for Bioadaptives SEC filings (Ticker: BDPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioAdaptives, Inc. filings document the company’s public-reporting obligations as an OTC operating company. The Form 12b-25 notice relates to a delayed Form 10-K for the year ended December 31, 2025 and identifies the annual report process under Rule 12b-25.
For this issuer, formal disclosures center on registrant identity, reporting deadlines, annual-report timing and related compliance statements rather than product-launch detail. The filing record provides regulatory context for BioAdaptives’ nutraceutical and wellness business as it reports as a public company.
BioAdaptives Inc. reported a net loss of $111,086 for the quarter ended March 31, 2026, an improvement from a loss of $197,136 a year earlier, as operating expenses declined. The company recorded its first reported revenues of $5,514, generating a small gross profit of $4,113, but its business remains at an early stage.
Liquidity is very tight. Cash was only $73,606 and total current assets $123,449, versus current liabilities of $2,272,091, resulting in a working capital deficit and a stockholders’ deficit of $2,136,142. This includes sizeable derivative liabilities of $1,563,920 and convertible notes of $424,211, all current.
Management states that recurring losses and the need for additional capital raise substantial doubt about the company’s ability to continue as a going concern. To conserve cash, BioAdaptives issued $105,000 of Series D preferred stock as compensation and continues to rely on related-party financing. Internal controls over financial reporting are deemed ineffective due to material weaknesses. The company is rolling out new nutraceutical and pet-health products, including PawPa Regen, MyndMed, Xcellara and, after quarter-end, the MyndSystem line, but these launches have not yet offset ongoing operating and financing pressures.
BioAdaptives, Inc. director Mark P. Frissora reported an award of Series D Convertible Preferred Stock as board compensation. He received 4,808 shares of Series D Convertible Preferred Stock as compensation for board services under a Board of Directors Agreement dated February 3, 2025.
Each Series D share is convertible into 100 shares of common stock, so this grant is currently linked to 480,800 common shares, subject to a 4.9% beneficial ownership limitation. The preferred shares generally cannot be converted for six months after issuance, except that conversion occurs immediately in a liquidation. Each preferred share carries 100 votes on stockholder matters, and the right to convert does not expire. Following this grant, Frissora directly holds 71,554 shares of Series D Convertible Preferred Stock.
BioAdaptives, Inc. reported very small revenues and mounting losses for the year ended December 31, 2025. Revenue was $18,278, while a net loss of $1,557,898 drove its accumulated deficit to $10,721,204. Operating expenses of $1,054,670 far exceeded sales as the company invested in product development, marketing, and professional services.
Cash was $158,445, and operations used $516,025 of cash, funded mainly by issuing Series D preferred stock and new convertible notes. The balance sheet shows derivative liabilities of $1,738,804 and convertible notes of $352,332. The independent auditor highlighted substantial doubt about the company’s ability to continue as a going concern.
BioAdaptives focuses on nutraceuticals and wellness products for humans and animals, including MyndMed™, Xcellara™, Zeranovia™ and PawPa® Regen, alongside an FDA‑cleared Lung Flute™ device. Several products are in development or pre‑launch, and the company plans to grow through direct‑to‑consumer marketing, telehealth partnerships, and affiliate programs, but remains dependent on external financing.
BIOADAPTIVES, INC. director Mark P. Frissora reported an other-type derivative transaction involving Series D Convertible Preferred Stock. He received 4,386 shares of Series D Convertible Preferred Stock as compensation for board services under a Board of Directors Agreement dated February 3, 2025, at a stated price of $0.0000 per share.
Each preferred share is convertible into 100 shares of common stock, for 438,600 underlying common shares, subject to a 4.9% beneficial ownership limitation. The preferred shares generally cannot be converted until six months after issuance, except upon liquidation, and each preferred share carries 100 votes on matters submitted to stockholders. Following this grant, Frissora directly holds 66,746 shares of Series D Convertible Preferred Stock.
BioAdaptives, Inc. submitted a Form 12b-25 notification stating it could not timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company attributes the delay to completing disclosures and finalizing financial statements with its independent public accountant. The notice is signed by James E. Keener, CEO on March 31, 2026.
BIOADAPTIVES, INC. director Mark P. Frissora reported an "other" transaction involving Series D Convertible Preferred Stock. He received 2,578 shares of this preferred stock as compensation for board services under a Board of Directors Agreement dated February 3, 2025, at a stated price of $0.00 per share, bringing his direct holdings to 62,360 shares.
Each share of Series D Convertible Preferred Stock is convertible into 100 shares of common stock, subject to a 4.9% beneficial ownership limitation, and generally cannot be converted for six months after issuance except upon liquidation. Each preferred share carries 100 votes on company matters, and the conversion right does not expire.
Bioadaptives, Inc. reported that director Mark P. Frissora received 2,565 shares of its Series D Convertible Preferred Stock on February 1, 2026, coded as a transaction "J" and issued at $0.00 per share as compensation for board services.
Following this grant, Frissora beneficially owns 59,779 Series D preferred shares. Each Series D share is convertible into 100 common shares, subject to a 4.9% beneficial ownership limitation, cannot be converted until six months after issuance (except on liquidation), carries 100 votes per share, and has a conversion right that does not expire.
BioAdaptives, Inc. director reports stock-based board compensation. A company director received 2,286 shares of BioAdaptives Series D Convertible Preferred Stock on 01/01/2026 as compensation for board services under a Board of Directors Agreement dated February 3, 2025. Each preferred share has a stated par value of $0.0001 and is convertible into 100 shares of common stock, for an underlying 228,600 common shares, subject to a 4.9% beneficial ownership limitation.
No Series D shares may be converted until six months after issuance, except that conversion occurs immediately upon liquidation. Each preferred share carries 100 votes in stockholder matters, and the conversion right does not expire. Following this transaction, the reporting person held 57,217 derivative securities in the form of Series D Convertible Preferred Stock, owned directly.
Bioadaptives, Inc. disclosed that a director filed a Form 4 reporting equity compensation in the form of preferred stock. On 12/01/2025, the director received 2,025 shares of Series D Convertible Preferred Stock as compensation for board services under a Board of Directors Agreement dated February 3, 2025. Each preferred share is convertible into 100 shares of common stock, for a total of 202,500 underlying common shares, but conversions are subject to a 4.9% beneficial ownership limitation.
The preferred shares generally cannot be converted until six months after issuance, except that conversion occurs immediately in a liquidation. Each preferred share carries 100 votes on stockholder matters and the conversion right does not expire. After this transaction, the reporting person beneficially owned 54,931 derivative securities, held directly.
BioAdaptives, Inc. (BDPT) reported Q3 2025 results, showing a wider net loss and continued liquidity pressure. Net loss was $379,502 for the quarter, compared with $37,649 a year ago, as operating expenses and derivative fair value changes weighed on results. Revenue reached $4,632 in Q3 as limited PawPa Regen sales began.
For the nine months, net loss totaled $734,552 on revenue of $7,851. Cash was $59,273 at September 30, 2025, with current assets of $108,860 versus current liabilities of $1,589,570, resulting in a working capital deficiency of $1,480,710. The company reported a stockholders’ deficit of $1,465,210, including derivative liabilities of $967,406 and convertible notes of $359,300.
Management disclosed substantial doubt about the company’s ability to continue as a going concern and noted material weaknesses in internal controls. Financing activities included $300,000 of cash proceeds from Series D preferred stock and debt-to-equity conversions. Common shares outstanding were 12,008,659 as of October 17, 2025.